Carl Oetker - STADA Arzneimittel Insider

STADA Arzneimittel Aktiengesellschaft -- USA Stock  

USD 106.55  0.000003  0.00%

Member of the Supervisory Board

Mr. Carl Ferdinand Oetker was Chairman of the Supervisory Board of STADA Arzneimittel AG from August 26, 2016 to September 25, 2017. He was Deputy Chairman of the Supervisory Board the Company from June 4, 2014 to August 26, 2016. Previously he served as Member of the Supervisory Board of STADA Arzneimittel AG since November 13, 2009 till June 4, 2014. He serves as Member of the Audit Committee, Human Resource and Nominating Committee at the Company. From 1991 till 1993, he served in Armored reconissance batalion as Reserve Officer. From 1997 till 1998, he served as Consultant in the International Financial Services Group at The Boston Consulting Group in Frankfurt am Main, Germany. From 1998 till 1999, he served as Assistant to the General Management, Manager in the Private Client Group at Schroder Fonds Service GmbH. From 1999 till 2002, he served as Authorized Representative at Senior Manager Institutional Advisory Co Team Leader Institutional Advisory and Director at AXA Investment Managers Deutschland GmbH. From 2002 till 2003, he served as Authorized Representative, Sector Team Industrials, Manufacturing, Electronics, Engineering, Corporationrationrate Client Business at ING BHFBANK Aktiengesellschaft. From 2005 till 2008, he served as Director and Area Manager North Region of Bankhaus Lampe KG in Hamburg, Germany. He was General Agent of Bankhaus Lampe KG since January 2009. In addition, he has held mandates in various mandates, including being Chairman of the Advisory Board of EWABO Chemikalien GmbH Co. KG, General Manager and Chairman of the Advisory Board of wink Stanzwerkzeuge GmbH Co. KG, Member of the Supervisory Board of DEV AS, and Member of the Board of Directors of Cloverfield Inc, among others.
Age: 43  Executive Since 2016      
49 6101 603 0

Management Efficiency

The company has return on total asset (ROA) of 5.45 % which means that it generated profit of $5.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 9.23 % meaning that it generated $9.23 on every $100 dollars invested by stockholders.
The company has accumulated 1.62 B in total debt with debt to equity ratio (D/E) of 130.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 0.64 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. STADA Arzneimittel is traded on OTC Market in USA.STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Stadastrasse 2-18 and employs 10,176 people.

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add STADA Arzneimittel Aktiengesellschaft to your portfolio

Top Management

STADA Arzneimittel A Leadership Team
Carl Oetker, Executive
JanNicolas Garbe, Executive
Dieter Koch, Executive
Eckhard Brueggemann, Executive, Ph.D
Mark Keatley, CFO
Ralph Grobecker, Managing Director, Ph.D
Martin Abend, Chairman, Ph.D
Matthias Wiedenfels, Executive, Ph.D
Arnold Hertzsch, Executive, Ph.D
Halil Duru, Executive
Tina Mueller, Executive
Engelbert Willink, Chairman
Barthold Piening, Executive, Ph.D
Helmut Kraft, CFO
Ute Pantke, Executive, Ph.D
Hartmut Retzlaff, Chairman
Bernhard Duettmann, CFO
Claudio Albrecht, Chairman, Ph.D
Michael Siefke, Executive
Leslie Iltgen, President
Eric Cornut, Executive
Jens Steegers, Executive
Birgit Kudlek, Executive, Ph.D
Guenter Au, Chairman, Ph.D
Constantin Meyer, Executive
Rolf Hoffmann, Executive, MBA
Markus Metzger, Director
Benjamin Kunstler, Executive
Gunnar Riemann, Executive, Ph.D
Bruno Schick, Executive

Stock Performance

STADA Arzneimittel Performance Indicators